Thanks for joining DividendStocks.com, the daily newsletter built for dividend and income investors like you. We’re thrilled to have you on board and can’t wait to help you discover the best dividend opportunities out there. Before we can start sending your daily insights, please take a quick moment to confirm your subscription: Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Why wait? Let’s get your dividend journey started! Click Here to Start Discovering Top Income-Generating Stocks See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
More Reading from MarketBeat Why Wall Street Gave Up on Pfizer—and Why That May Be a MistakeReported by Jeffrey Neal Johnson. Published: 12/31/2025. 
What You Need to Know - Pfizer trades at a historic discount compared to its peers while paying a dividend yield that significantly outperforms the broader market average.
- Strategic acquisitions have established a robust pipeline of next-generation cancer treatments, which are driving growth.
- Management has aggressively re-entered the weight-loss market with new assets, including one that offers a convenient monthly dosing schedule for patients.
The market of 2025 will be remembered for its extremes. While investors poured billions into technology sector giants and companies manufacturing weight-loss drugs, traditional pharmaceutical leaders were left in the cold. Nowhere is this more evident than with Pfizer Inc. (NYSE: PFE). Trading near multi-year lows around $25, the company finishes the year as one of the most unloved assets in the S&P 500. For the casual observer, that pessimism seems justified: the firm has spent the last two years battling a perfect storm. A free report revealing the 7 key indicators that have predicted every major economic collapse since 1929.
Right now, all seven are flashing red simultaneously for the first time since 2007.
These aren't the signals you'll see on CNBC. Claim Your Free Report Now » Revenue from COVID-19 products vanished faster than anticipated, several high-profile pipeline candidates failed in clinical trials, and activist investors waged a public campaign against management. But sharp investing often means looking where others won't. With the exit of activist investor Starboard Value in November and a realistic reset of financial guidance, the worst of that storm appears to have passed. The bad news is largely priced in, and Pfizer's stock price has likely found a floor. Entering 2026, Pfizer presents a rare scenario: a blue-chip company trading at distressed levels, paying a solid dividend while it quietly rebuilds its growth engine. The Mathematical Case: Why the Price Is Wrong For value investors, the case for Pfizer comes down to simple math. The market is pricing the company as if its earnings will permanently shrink, creating a wide disconnect between the share price and the company's likely cash generation. A Historic Valuation Gap Pfizer currently trades at a forward price-to-earnings ratio (P/E) of roughly 8.6x. By comparison, the average company in the pharmaceutical sector trades at 15x to 20x earnings, and high-growth peers such as Eli Lilly (NYSE: LLY) command much higher multiples. A valuation near 8.6x implies the market expects virtually no growth — a low bar. Pfizer doesn't need a miracle to see its stock recover; it simply needs to demonstrate stability. Any positive earnings surprise could prompt a multiple expansion as the stock re-rates toward peers. The Dividend Shield While investors wait for that repricing, they are paid handsomely to hold the shares. - Annual Payout: $1.72 per share.
- Current Yield: Approximately 6.9%.
That yield is nearly four times the S&P 500 average and serves as a margin of safety. Even if the stock remains flat through 2026, a near-7% dividend provides a baseline return that outperforms most savings accounts and government bonds. Management is protecting the dividend with a $4 billion cost-saving initiative. By trimming administrative bloat and optimizing manufacturing, they are preserving the cash flow needed to keep those quarterly checks flowing. The New Foundation: Oncology Takes the Lead One common criticism is that Pfizer still has a growth gap following the decline of its COVID business. To fill that gap, the company has pivoted aggressively toward oncology. Guided-Missile Technology The crown jewel of Pfizer's 2023 Seagen acquisition is leadership in Antibody-Drug Conjugates (ADCs). Where traditional chemotherapy is a broad blast that harms healthy as well as cancerous cells, ADCs act more like guided missiles: they target specific cancer cells and deliver a toxic payload directly, sparing healthy tissue. This approach is already contributing revenue. The Seagen portfolio added approximately $3.4 billion in 2024 and produced strong results driven by sales of Padcev for bladder cancer. Navigating the Bumps The path hasn't been smooth. In December 2025 the company reported a safety signal involving Hympavzi, which included a patient death in an extended trial. While that development caused a temporary market reaction, it does not derail the broader thesis. The oncology portfolio remains deep, with more than 60 programs in development. Pfizer has also bolstered its pipeline by licensing a promising bispecific antibody from 3SBio, underscoring ongoing efforts to bring new potential blockbusters forward. Catching Up: The Strategy for Weight Loss In early 2025 Wall Street wrote Pfizer off in the lucrative weight-loss drug race after the internal oral candidate Danuglipron failed to progress. Abandoning the biggest medical trend of the decade was never an option. In late 2025 Pfizer re-entered the field through two strategic deals. The Injectable Strategy (Metsera) In November, Pfizer acquired Metsera for about $7 billion. The deal gave it ownership of a next-generation injectable (MET-097i) that could be administered monthly rather than weekly — a meaningful convenience advantage if clinical results hold up. The Oral Strategy (YaoPharma) Recognizing that some patients prefer pills, Pfizer also licensed a small-molecule GLP-1 candidate from YaoPharma, giving it a foothold in the oral weight-loss market. Why This Matters Today's share price largely assigns zero value to Pfizer's obesity pipeline, effectively creating a free option for investors. Because expectations are so low, any clinical or commercial progress from the Metsera or YaoPharma assets would represent pure upside. Pfizer doesn't need to be first; it just needs to capture a meaningful slice of what is expected to be a multibillion-dollar market. The Risk/Reward Equation: 2026 Belongs to Value Pfizer enters 2026 as a company in transition with a fortified balance sheet. Management has set a revenue floor of roughly $61 billion for 2026 — a realistic target that removes much of the uncertainty that weighed on the stock. For investors the math is straightforward. At about $25 per share, downside is cushioned by a high dividend and a valuation at historic lows. The upside is substantial: continued oncology growth or positive developments in the weight-loss pipeline could trigger a sharp re-rating. Unloved stocks one year often become standout performers the next. With the activist drama behind it and the balance sheet stabilized, Pfizer has shifted from a falling knife to a potential foundational holding for value-oriented portfolios. For Pfizer, 2026 may be the year the sleeping giant wakes up.
| 
